Steve Zenker; Vice President of Investor Relations; Medifast Inc. Daniel Chard; Chairman of the Board, Chief Executive Officer; Medifast Inc. James Maloney; Chief Fi ...

Discover how Medifast navigates GLP-1 market shifts with innovative products like OPTAVIA ASCEND, cost-saving initiatives, and growth strategies for 2025.

Medifast has a 52-week low of $14.76 and a 52-week high of $52.96. The company has a quick ratio of 2.55, a current ratio of 3.11 and a debt-to-equity ratio of 0.06. The company’s 50-day simple ...

These products are featured in two new science-backed nutrition plans designed ... With its stock down 15% over the past week, it is easy to disregard Medifast (NYSE:MED). It is possible that the ...

These compounds take a different approach to weight loss than existing medications, which can cause nausea, vomiting and gastric malaise. GLP-1 receptor targeting has been successful for weight loss ...

Researchers from across the country believe they have developed a breakthrough weight loss drug treatment: two new peptide compounds ... in the first four weeks, according to a May 2024 study ...

I'm sure Tyler will lose the race lead tomorrow, but later in the week I think he'll be contesting ... Johnny Sundt (Kelly Benefits Strategies-Medifast) decided to try and bridge up. For the next 20 ...

Two Weeks in August, an original eight-part drama series from the makers of I May Destroy You and Such Brave Girls, will go into production soon This is a story about what it’s like to try and ...